{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:31:09Z","timestamp":1763638269527,"version":"3.45.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent case reports linked use of the lipid-lowering class of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors to severe hypersensitivity reactions. Therefore, our pharmacovigilance study assessed the association between reporting of PCSK9 inhibitors and hypersensitivity or anaphylaxis. We analyzed the US Food and Drug Administration Adverse Event Reporting System (FAERS) extracting spontaneous reports from 2015 to 2023. We calculated reporting odds ratios (ROR), proportional reporting ratios, and information components (IC) as measures of disproportionate reporting of hypersensitivity or anaphylaxis with PCSK9 inhibitors overall and with specific compounds (alirocumab, evolocumab) using the entire FAERS as comparator. In sensitivity analyses, we adjusted for demographic characteristics, used statins as active comparator, and applied alternate outcome definitions. Among all reports in FAERS during the study period involving PCSK9 inhibitors, we identified 12,591 cases of hypersensitivity and 17,214 cases of anaphylaxis. Across disproportionality analysis methods, we did not observe an association between the reporting of PCSK9 inhibitors or evolocumab specifically and the outcomes. However, there were associations with alirocumab and hypersensitivity (ROR, 1.14; 95% confidence interval [CI], 1.11\u20131.18 \/ IC, 0.19; 95% credible interval [CrI], 0.14\u20130.24) and with alirocumab and anaphylaxis (ROR, 1.30; 95% CI, 1.26\u20131.33; IC, 0.37; 95% CrI, 0.33\u20130.42). Sensitivity analyses corroborated the lack of an association with PCSK9 inhibitors or with evolocumab and were inconsistent regarding alirocumab. Our large pharmacovigilance study showed no signal of disproportionate reporting for hypersensitivity or anaphylaxis with PCSK9 inhibitors overall. The inconsistencies in alirocumab related findings argue against a compound specific signal.<\/jats:p>","DOI":"10.1038\/s41598-025-24945-1","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:26:07Z","timestamp":1763637967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A disproportionality analysis on proprotein convertase subtilisin\/kexin type 9 inhibitors and hypersensitivity and anaphylaxis"],"prefix":"10.1038","volume":"15","author":[{"given":"Foteini","family":"Dermiki-Gkana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Gravel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Kontogiorgis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonios","family":"Douros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"issue":"3","key":"24945_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14656566.2019.1702970","volume":"21","author":"A Pasta","year":"2020","unstructured":"Pasta, A. et al. PCSK9 inhibitors for treating hypercholesterolemia. Expert Opin. Pharmacother. 21 (3), 353\u2013363 (2020).","journal-title":"Expert Opin. Pharmacother"},{"issue":"22","key":"24945_CR2","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz, G. G. et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl. J. Med. 379 (22), 2097\u20132107 (2018).","journal-title":"N Engl. J. Med."},{"issue":"18","key":"24945_CR3","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl. J. Med. 376 (18), 1713\u20131722 (2017).","journal-title":"N Engl. J. Med."},{"issue":"16","key":"24945_CR4","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson, J. G. et al. Efficacy and safety of Alirocumab in reducing lipids and cardiovascular events. N Engl. J. Med. 372 (16), 1489\u20131499 (2015).","journal-title":"N Engl. J. Med."},{"issue":"4","key":"24945_CR5","doi-asserted-by":"publisher","first-page":"574","DOI":"10.5603\/CJ.a2021.0110","volume":"29","author":"Q Geng","year":"2022","unstructured":"Geng, Q., Li, X., Sun, Q. & Wang, Z. Efficacy and safety of PCSK9 Inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials. Cardiol. J. 29 (4), 574\u2013581 (2022).","journal-title":"Cardiol. J."},{"key":"24945_CR6","doi-asserted-by":"crossref","unstructured":"Mulverstedt, S. et al. P706 treatment of hypercholesterolaemia with PCSK-9 inhibitors in Denmark. Assessment of real-life data; safety an extent of adverse effects after the first years of clinical use. Eur. Heart J.  40(Supplement_1) (2019).","DOI":"10.26226\/morressier.5cc04c41c66852000b5ae7bc"},{"issue":"9","key":"24945_CR7","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1016\/j.jaip.2021.06.012","volume":"9","author":"SSY Lam","year":"2021","unstructured":"Lam, S. S. Y. et al. First confirmed case of IgE-mediated hypersensitivity to evolucumab with cross-reactivity to Alirocumab. J. Allergy Clin. Immunol. Pract. 9 (9), 3481\u20133482e1 (2021).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"24945_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","volume":"228","author":"AL Catapano","year":"2013","unstructured":"Catapano, A. L. & Papadopoulos, N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 228 (1), 18\u201328 (2013).","journal-title":"Atherosclerosis"},{"key":"24945_CR9","unstructured":"Pokhrel, B. P. M. & Levine, S. N. PCSK9 inhibitors. In StatPearls [Internet]. (StatPearls Publishing, 2024) https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK448100\/"},{"key":"24945_CR10","unstructured":"FDA - April - June. 2018 | Potential Signals of Serious Risks\/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS). https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/april-june-2018-potential-signals-serious-risksnew-safety-information-identified-fda-adverse-event"},{"key":"24945_CR11","unstructured":"U.S. Food and Drug Association Adverse Event Reporting System (AERS). https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard"},{"key":"24945_CR12","unstructured":"Farrell, P. J., Gravel, C. A. & Krewski, D. Statistical Methods for Signal Detection in Spontaneous Reporting Databases. The Encyclopedia of Biopharmaceutical Statistics. 2068\u20132083 (CRC Press, Taylor & Francis Group, 2018)."},{"issue":"6","key":"24945_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M. et al. The reporting of A disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration. Drug Saf. 47 (6), 585\u2013599 (2024).","journal-title":"Drug Saf."},{"issue":"6","key":"24945_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 10 (6), 483\u2013486 (2001).","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"8","key":"24945_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 13 (8), 519\u2013523 (2004).","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"4","key":"24945_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54 (4), 315\u2013321 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"24945_CR17","doi-asserted-by":"crossref","unstructured":"Gravel, C. A., Bai, W. & Douros, A. Comparators in pharmacovigilance: A quasi-quantification bias analysis. Drug Saf. (2024).","DOI":"10.1007\/s40264-024-01433-5"},{"issue":"9","key":"24945_CR18","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1111\/bcp.15802","volume":"89","author":"CA Gravel","year":"2023","unstructured":"Gravel, C. A. & Douros, A. Considerations on the use of different comparators in pharmacovigilance: A methodological review. Br. J. Clin. Pharmacol. 89 (9), 2671\u20132676 (2023).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"24945_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund, J. L., Richardson, D. B. & Sturmer, T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr. Epidemiol. Rep. 2 (4), 221\u2013228 (2015).","journal-title":"Curr. Epidemiol. Rep."},{"issue":"3","key":"24945_CR20","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","volume":"2","author":"FA Harding","year":"2010","unstructured":"Harding, F. A., Stickler, M. M., Razo, J. & DuBridge, R. B. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2 (3), 256\u2013265 (2010).","journal-title":"MAbs"},{"issue":"6","key":"24945_CR21","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jaci.2009.09.009","volume":"124","author":"PJ Brennan","year":"2009","unstructured":"Brennan, P. J., Rodriguez Bouza, T., Hsu, F. I., Sloane, D. E. & Castells, M. C. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J. Allergy Clin. Immunol. 124 (6), 1259\u20131266 (2009).","journal-title":"J. Allergy Clin. Immunol."},{"key":"24945_CR22","first-page":"1","volume-title":"Handbook of Epidemiology","author":"E Garbe","year":"2022","unstructured":"Garbe, E., Suissa, S. & Douros, A. Pharmacoepidemiology. In  Handbook of Epidemiology (eds Ahrens, W. & Pigeot, I.). 1\u201355 (Springer, 2022)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24945-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24945-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24945-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:26:09Z","timestamp":1763637969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24945-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24945"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-24945-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"10 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41137"}}